<DOC>
	<DOCNO>NCT01724528</DOCNO>
	<brief_summary>The purpose study determine whether febuxostat superior allopurinol prevention tumor lysis syndrome ( TLS ) patient hematological malignancy intermediate high risk TLS ( accord Cairo-Bishop classification ) undergo chemotherapy</brief_summary>
	<brief_title>Febuxostat Tumor Lysis Syndrome Prevention Hematologic Malignancies</brief_title>
	<detailed_description>This study design randomise , double-blind , active-controlled , parallel-group study conduct approximately 80 site . Approximately 340 male female patient age 18 old suffer hematologic malignancy ( de novo patient relapse patient ) intermediate high risk TLS schedule receive first cycle cytotoxic chemotherapy , regardless line treatment , randomize study . Eligible patient ( per screen visit ) randomly allocate 1:1 ratio Febuxostat Allopurinol . The double-blind treatment period start two day prior plan begin chemotherapy continue 7 9 consecutive day , accord Investigator judgment basis actual duration chemotherapy regimen administer patient . Along study treatment , uric acid level , creatinine level , Laboratory TLS/Clinical TLS Adverse Events represent major clinical finding monitor daily basis . Overall study encompass 10 11 plan visit site , include screening , randomisation , treatment final follow visit .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tumor Lysis Syndrome</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>Patients schedule first cytotoxic chemotherapy cycle , regardless line treatment , hematologic malignancy intermediate high risk TLS ( accord TLS risk stratification , Cairo M et al , British Journal Haematology , 2010 ) candidate Allopurinol treatment access Rasburicase Eastern Cooperative Oncology Group ( ECOG ) performance status 0 3 Life expectancy &gt; 1 month Patients know hypersensitive Febuxostat Allopurinol component formulation Patients sUA level â‰¥ 10 mg/dL randomization Patients receive Febuxostat , Allopurinol urate lower therapy ( e.g . Rasburicase , probenecid ) within 30 day prior randomization Patients severe renal and/or hepatic insufficiency Patients diagnosis LTLS CTLS randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Febuxostat , Tumor lysis syndrome , leukemia , lymphoma</keyword>
</DOC>